Cargando…

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction

The significant morbidity and mortality associated with heart failure with reduced (HFrEF) or preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. The nitric oxide (NO)–soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays an important ro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aimo, Alberto, Castiglione, Vincenzo, Vergaro, Giuseppe, Panichella, Giorgia, Senni, Michele, Lombardi, Carlo Mario, Emdin, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197896/ https://www.ncbi.nlm.nih.gov/pubmed/34291399 http://dx.doi.org/10.1007/s10741-021-10146-1

Ejemplares similares

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Value of the HFA‐PEFF and H(2)FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
por: Falco, Luigi, et al.
Publicado: (2023)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022)

Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
por: Chianca, Michela, et al.
Publicado: (2022)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
por: Hammer, Andreas, et al.
Publicado: (2023)

ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

Prognostic Value of sST2 in Heart Failure
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Role of Imaging in Cardiomyopathies
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

Current and emerging drug targets in heart failure treatment
por: Ghionzoli, Nicolò, et al.
Publicado: (2021)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Risk stratification in heart failure with mild reduced ejection fraction
por: Magrì, Damiano, et al.
Publicado: (2020)

Subclinical cardiac damage in cancer patients before chemotherapy
por: Fabiani, Iacopo, et al.
Publicado: (2021)

Cardiovascular toxicity from therapies for light chain amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2023)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
por: Sciatti, Edoardo, et al.
Publicado: (2022)

Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction
por: Gori, Mauro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ehfjutlmhpr2tpd5kesrllq70l